[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biocryst Pharma Inc (BCRX)

Biocryst Pharma Inc (BCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,373,882
  • Shares Outstanding, K 254,163
  • Annual Sales, $ 874,840 K
  • Annual Income, $ 263,860 K
  • EBIT $ -382 M
  • EBITDA $ -385 M
  • 60-Month Beta 0.55
  • Price/Sales 2.73
  • Price/Cash Flow 7.58
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 72.57% (+1.56%)
  • Historical Volatility 50.65%
  • IV Percentile 65%
  • IV Rank 23.43%
  • IV High 200.70% on 03/10/26
  • IV Low 33.36% on 08/26/25
  • Expected Move (DTE 24) 1.24 (12.95%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 1,612
  • Volume Avg (30-Day) 2,821
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 90,607
  • Open Int (30-Day) 100,278
  • Expected Range 8.34 to 10.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.14
  • Number of Estimates 3
  • High Estimate $0.31
  • Low Estimate $0.02
  • Prior Year $0.15
  • Growth Rate Est. (year over year) -6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.95 +7.04%
on 07/17/26
11.22 -14.62%
on 07/09/26
-0.36 (-3.62%)
since 06/26/26
3-Month
7.78 +23.06%
on 05/06/26
11.22 -14.62%
on 07/09/26
+0.68 (+7.64%)
since 04/27/26
52-Week
6.00 +59.67%
on 10/14/25
11.22 -14.62%
on 07/09/26
+1.03 (+12.05%)
since 07/25/25

Most Recent Stories

More News
BioCryst to Report Second Quarter 2026 Financial Results on August 5

RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results...

BCRX : 9.58 (+2.57%)
BioCryst Appoints David W. Jenkins as Chief Scientific Officer

RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) (“BioCryst” or the “Company”) today announced the appointment of David W. Jenkins,...

BCRX : 9.58 (+2.57%)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...

BCRX : 9.58 (+2.57%)
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

—Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth— —Completes enrollment in Phase 3 ALPHA-ORBIT for navenibart,...

BCRX : 9.58 (+2.57%)
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

— Growing body of ORLADEYO ® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations —...

BCRX : 9.58 (+2.57%)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...

BCRX : 9.58 (+2.57%)
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances

BioCryst Pharmaceuticals (NASDAQ:BCRX) CEO Charlie Gayer said the company remains on track with its commercial and development plans during a Jefferies fireside chat, highlighting continued growth expectations...

BCRX : 9.58 (+2.57%)
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema...

BCRX : 9.58 (+2.57%)
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 International...

BCRX : 9.58 (+2.57%)
BioCryst: Q1 Earnings Snapshot

BioCryst: Q1 Earnings Snapshot

BCRX : 9.58 (+2.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential...

See More

Key Turning Points

3rd Resistance Point 10.13
2nd Resistance Point 10.02
1st Resistance Point 9.80
Last Price 9.58
1st Support Level 9.47
2nd Support Level 9.36
3rd Support Level 9.14

See More

52-Week High 11.22
Last Price 9.58
Fibonacci 61.8% 9.23
Fibonacci 50% 8.61
Fibonacci 38.2% 7.99
52-Week Low 6.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.